Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review

Clinical Gastroenterology and Hepatology

Volumn 16, Issue 9, 2018, Pages 1407-1419.e22

  Ma, Christopher ^a,b   Hussein, Isra M ^c   Al Abbar, Yousef J ^d   Panaccione, Remo ^a   Fedorak, Richard N ^e   Parker, Claire E ^b   Nguyen, Tran M ^b   Khanna, Reena ^b,f   Siegel, Corey A ^g   Peyrin Biroulet, Laurent ^h   Pai, Rish K ^b,i   Vande Casteele, Niels ^b,j   D'Haens, Geert R ^b,k   Sandborn, William J ^b,j   Feagan, Brian G ^b,f   Jairath, Vipul ^b,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

Effects; IBD; Inflammatory Bowel Disease; RCT; Treatment

Indexed keywords

AMINOSALICYLIC ACID; BIOLOGICAL FACTOR; CORTICOSTEROID DERIVATIVE; IMMUNOMODULATING AGENT; PLACEBO; ANTIINFLAMMATORY AGENT;

CONCEPTUAL FRAMEWORK; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DISEASE SEVERITY ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REVIEW; RUTGEERTS SCORE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; ADVERSE DRUG REACTION; AGED; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85051144025     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.02.051     Document Type: Review

References (145)

1. Jairath, V., Levesque, B.G., Vande Casteele, N., et al. Evolving concepts in phases I and II drug development for Crohn's disease. J Crohns Colitis 11 (2017), 246–255.
2. Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
3. United States Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims 2009. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed December 15, 2017.
4. Williet, N., Sandborn, W.J., Peyrin-Biroulet, L., Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 12 (2014), 1246–1256.e6.
5. Mary, J.Y., Modigliani, R., Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study—Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989), 983–989.
6. Daperno, M., D'Haens, G., Van Assche, G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004), 505–512.
7. Khanna, R., Nelson, S.A., Feagan, B.G., et al. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev, 2016 CD010642.
8. Al-Bawardy, B., Hansel, S.L., Fidler, J.L., et al. Endoscopic and radiographic assessment of Crohn's disease. Gastroenterol Clin North Am 46 (2017), 493–513.
9. Novak, G., Parker, C.E., Pai, R.K., et al. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev, 7, 2017, CD012351.
10. Ma, C., Panaccione, R., Fedorak, R.N., et al. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open, 7, 2017, e016146.
11. Williamson, P.R., Altman, D.G., Blazeby, J.M., et al. Developing core outcome sets for clinical trials: issues to consider. Trials, 13, 2012, 132.
12. Best, W.R., Becktel, J.M., Singleton, J.W., et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
13. Harvey, R.F., Bradshaw, J.M., A simple index of Crohn's-disease activity. Lancet, 1, 1980, 514.
14. Summers, R.W., Switz, D.M., Sessions, J.T. Jr., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77:Pt 2 (1979), 847–869.
15. Malchow, H., Ewe, K., Brandes, J.W., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 (1984), 249–266.
16. Brynskov, J., Freund, L., Rasmussen, S.N., et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 321 (1989), 845–850.
17. Ewe, K., Press, A.G., Singe, C.C., et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105 (1993), 367–372.
18. Singleton, J.W., Hanauer, S.B., Gitnick, G.L., et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial—Pentasa Crohn's Disease Study Group. Gastroenterology 104 (1993), 1293–1301.
19. Greenberg, G.R., Feagan, B.G., Martin, F., et al. Oral budesonide for active Crohn's disease: Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331 (1994), 836–841.
20. Jewell, D.P., Lennard-Jones, J.E., Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 6 (1994), 499–506.
21. Tremaine, W.J., Schroeder, K.W., Harrison, J.M., et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 19 (1994), 278–282.
22. Candy, S., Wright, J., Gerber, M., et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 (1995), 674–678.
23. Feagan, B.G., Rochon, J., Fedorak, R.N., et al. Methotrexate for the treatment of Crohn's disease: the North American Crohn's Study Group Investigators. N Engl J Med 332 (1995), 292–297.
24. Stange, E.F., Modigliani, R., Pena, A.S., et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study—the European Study Group. Gastroenterology 109 (1995), 774–782.
25. Oren, R., Moshkowitz, M., Odes, S., et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 92 (1997), 2203–2209.
26. Stack, W.A., Mann, S.D., Roy, A.J., et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349 (1997), 521–524.
27. Targan, S.R., Hanauer, S.B., van Deventer, S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997), 1029–1035.
28. van Deventer, S.J., Elson, C.O., Fedorak, R.N., Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease: Crohn's Disease Study Group. Gastroenterology 113 (1997), 383–389.
29. Yacyshyn, B.R., Bowen-Yacyshyn, M.B., Jewell, L., et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114 (1998), 1133–1142.
30. D'Haens, G., Van Deventer, S., Van Hogezand, R., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116 (1999), 1029–1034.
31. Sandborn, W.J., Tremaine, W.J., Wolf, D.C., et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease: North American Azathioprine Study Group. Gastroenterology 117 (1999), 527–535.
32. Sands, B.E., Bank, S., Sninsky, C.A., et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 117 (1999), 58–64.
33. Fedorak, R.N., Gangl, A., Elson, C.O., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease: the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119 (2000), 1473–1482.
34. Schreiber, S., Fedorak, R.N., Nielsen, O.H., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease: Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119 (2000), 1461–1472.
35. Carty, E., Rampton, D.S., Schneider, H., et al. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Aliment Pharmacol Ther 15 (2001), 1323–1329.
36. Gordon, F.H., Lai, C.W., Hamilton, M.I., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121 (2001), 268–274.
37. Sandborn, W.J., Feagan, B.G., Hanauer, S.B., et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120 (2001), 1330–1338.
38. Sandborn, W.J., Hanauer, S.B., Katz, S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001), 1088–1094.
39. Sands, B.E., Winston, B.D., Salzberg, B., et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16 (2002), 399–406.
40. Tremaine, W.J., Hanauer, S.B., Katz, S., et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 97 (2002), 1748–1754.
41. Ghosh, S., Goldin, E., Gordon, F.H., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003), 24–32.
42. Ito, H., Takazoe, M., Fukuda, Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004), 989–996 discussion 47.
43. Mannon, P.J., Fuss, I.J., Mayer, L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004), 2069–2079.
44. Sandborn, W.J., Feagan, B.G., Radford-Smith, G., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53 (2004), 1485–1493.
45. Winter, T.A., Wright, J., Ghosh, S., et al. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 20 (2004), 1337–1346.
46. Korzenik, J.R., Dieckgraefe, B.K., Valentine, J.F., et al. Sargramostim for active Crohn's disease. N Engl J Med 352 (2005), 2193–2201.
47. Sandborn, W.J., Colombel, J.F., Enns, R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005), 1912–1925.
48. Schreiber, S., Rutgeerts, P., Fedorak, R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005), 807–818.
49. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006), 323–333 quiz 591.
50. Hommes, D.W., Mikhajlova, T.L., Stoinov, S., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 (2006), 1131–1137.
51. Lemann, M., Mary, J.Y., Duclos, B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006), 1054–1061.
52. Reinisch, W., Hommes, D.W., Van Assche, G., et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55 (2006), 1138–1144.
53. Rutgeerts, P., Sandborn, W.J., Fedorak, R.N., et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006), 888–893.
54. Schreiber, S., Feagan, B., D'Haens, G., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006), 325–334.
55. Feagan, B.G., Anderson, F., Radford-Smith, G.L., et al. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of N.O.V.E.L. 4, a phase III multicenter study. Gastroenterology, 132, 2007, A103.
56. Mansfield, J.C., Parkes, M., Hawthorne, A.B., et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther 26 (2007), 421–430.
57. Sandborn, W.J., Rutgeerts, P., Enns, R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007), 829–838.
58. Sandborn, W.J., Feagan, B.G., Stoinov, S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007), 228–238.
59. Targan, S.R., Feagan, B.G., Fedorak, R.N., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132 (2007), 1672–1683.
60. Yacyshyn, B., Chey, W.Y., Wedel, M.K., et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 5 (2007), 215–220.
61. Feagan, B.G., Greenberg, G.R., Wild, G., et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 6 (2008), 1370–1377.
62. Sandborn, W.J., Feagan, B.G., Fedorak, R.N., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135 (2008), 1130–1141.
63. Takazoe, M., Watanabe, M., Kawaguchi, T., et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease — a randomized, double-blind, placebo-controlled trial. Gastroenterology, 136, 2009 A-181.
64. Valentine, J.F., Fedorak, R.N., Feagan, B., et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut 58 (2009), 1354–1362.
65. Dotan, I., Rachmilewitz, D., Schreiber, S., et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 59 (2010), 760–766.
66. Reinisch, W., de Villiers, W., Bene, L., et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 16 (2010), 233–242.
67. Sands, B.E., Jacobson, E.W., Sylwestrowicz, T., et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 16 (2010), 1209–1218.
68. van der Woude, C.J., Stokkers, P., van Bodegraven, A.A., et al. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm Bowel Dis 16 (2010), 1708–1716.
69. Sandborn, W.J., Schreiber, S., Feagan, B.G., et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 9 (2011), 670–678.e3.
70. Sandborn, W.J., Ghosh, S., Panes, J., et al. Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease. Gastroenterology, 140, 2011 S-124.
71. Hueber, W., Sands, B.E., Lewitzky, S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
72. Rutgeerts, P., Van Assche, G., Sandborn, W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142 (2012), 1102–1111.e2.
73. Sandborn, W.J., Gasink, C., Gao, L.L., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367 (2012), 1519–1528.
74. Watanabe, M., Hibi, T., Lomax, K.G., et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 6 (2012), 160–173.
75. Keshav, S., Vanasek, T., Niv, Y., et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One, 8, 2013, e60094.
76. Sandborn, W.J., Feagan, B.G., Rutgeerts, P., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711–721.
77. Suzuki, Y., Motoya, S., Takazoe, M., et al. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis 7 (2013), 239–247.
78. D'Haens, G., Sandborn, W.J., Colombel, J.F., et al. A phase II study of laquinimod in Crohn's disease. Gut 64 (2015), 1227–1235.
79. Sandborn, W.J., Ghosh, S., Panes, J., et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol 12 (2014), 1485–1493.
80. Sands, B.E., Feagan, B.G., Rutgeerts, P., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 147 (2014), 618–627.e3.
81. Eser, A., Colombel, J.F., Rutgeerts, P., et al. Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn's disease: a randomized placebo-controlled, double-blind, Phase IIa study. Inflamm Bowel Dis 21 (2015), 2247–2253.
82. Feagan, B.G., Sandborn, W.J., D'Haens, G., et al. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther 42 (2015), 1170–1181.
83. Panaccione, R., Sandborn, W.J., Gordon, G.L., et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis 21 (2015), 1329–1340.
84. Danese, S., Vermeire, S., Hellstern, P., et al. Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's disease who are antitumour necrosis factor inadequate responders. J Crohns Colitis 10 (2016), S12–S13.
85. Feagan, B.G., Sandborn, W.J., Gasink, C., et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375 (2016), 1946–1960.
86. Targan, S.R., Feagan, B., Vermeire, S., et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol 111 (2016), 1599–1607.
87. Feagan, B.G., Sandborn, W.J., D'Haens, G., et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389 (2017), 1699–1709.
88. Panes, J., Sandborn, W.J., Schreiber, S., et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut, 16, 2017, 16.
89. Sandborn, W.J., Rutgeerts, P., Colombel, J.F., et al. Eldelumab [anti-interferon-gamma-inducible protein-10 antibody] induction therapy for active Crohn's disease: a randomised, double-blind, placebo-controlled phase IIa study. J Crohns Colitis, 22, 2017, 22.
90. Sandborn, W.J., Lee, S.D., Tarabar, D., et al. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut, 2017 e-pub ahead of print.
91. Sands, B.E., Chen, J., Feagan, B.G., et al. Efficacy and aafety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology 153 (2017), 77–86.e6.
92. Vermeire, S., Schreiber, S., Petryka, R., et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389 (2017), 266–275.
93. Williams, S.E., Grundman, M.J., Baker, R.D., et al. A controlled trial of disodium cromoglycate in the treatment of Crohn's disease. Digestion 20 (1980), 395–398.
94. Prantera, C., Pallone, F., Brunetti, G., et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease: the Italian IBD Study Group. Gastroenterology 103 (1992), 363–368.
95. Gendre, J.P., Mary, J.Y., Florent, C., et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study—the Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 104 (1993), 435–439.
96. Feagan, B.G., McDonald, J.W., Rochon, J., et al. Low-dose cyclosporine for the treatment of Crohn's disease: the Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 330 (1994), 1846–1851.
97. Thomson, A.B., Wright, J.P., Vatn, M., et al. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 9 (1995), 673–683.
98. Greenberg, G.R., Feagan, B.G., Martin, F., et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study—Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110 (1996), 45–51.
99. Modigliani, R., Colombel, J.F., Dupas, J.L., et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 110 (1996), 688–693.
100. de Franchis, R., Omodei, P., Ranzi, T., et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 11 (1997), 845–852.
101. Sutherland, L.R., Martin, F., Bailey, R.J., et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease: the Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 112 (1997), 1069–1077.
102. Ferguson, A., Campieri, M., Doe, W., et al. Oral budesonide as maintenance therapy in Crohn's disease: results of a 12-month study—Global Budesonide Study Group. Aliment Pharmacol Ther 12 (1998), 175–183.
103. Gross, V., Andus, T., Ecker, K.W., et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease: the Budesonide Study Group. Gut 42 (1998), 493–496.
104. Rutgeerts, P., D'Haens, G., Targan, S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999), 761–769.
105. Feagan, B.G., Fedorak, R.N., Irvine, E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease: North American Crohn's Study Group Investigators. N Engl J Med 342 (2000), 1627–1632.
106. Cortot, A., Colombel, J.F., Rutgeerts, P., et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 48 (2001), 186–190.
107. Fedorak, R.N., Nielsen, O.H., Williams, N.C., et al. Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease. Gastroenterology, 120, 2001, A127.
108. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002), 1541–1549.
109. Sands, B.E., Anderson, F.H., Bernstein, C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004), 876–885.
110. Feagan, B.G., Sandborn, W.J., Baker, J.P., et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 21 (2005), 373–384.
111. Hanauer, S., Sandborn, W.J., Persson, A., et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 21 (2005), 363–371.
112. Lemann, M., Mary, J.Y., Colombel, J.F., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128 (2005), 1812–1818.
113. Feagan, B.G., Sandborn, W.J., Lichtenstein, G., et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 23 (2006), 617–628.
114. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007), 52–65.
115. Sandborn, W.J., Hanauer, S.B., Rutgeerts, P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56 (2007), 1232–1239.
116. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007), 239–250.
117. Reinisch, W., Panes, J., Lemann, M., et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 103 (2008), 2284–2292.
118. Pena Rossi, C., Hanauer, S.B., Tomasevic, R., et al. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol, 9, 2009, 22.
119. Panaccione, R., Sandborn, W.J., Gordon, G., et al. Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn's disease (CD). Am J Gastroenterol, 105(S1), 2010, S457.
120. Panes, J., Lopez-Sanroman, A., Bermejo, F., et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 145 (2013), 766–774e1.
121. Ewe, K., Herfarth, C., Malchow, H., et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42 (1989), 224–232.
122. Brignola, C., Cottone, M., Pera, A., et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease: Italian Cooperative Study Group. Gastroenterology 108 (1995), 345–349.
123. Hellers, G., Cortot, A., Jewell, D., et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease: the IOIBD Budesonide Study Group. Gastroenterology 116 (1999), 294–300.
124. Lochs, H., Mayer, M., Fleig, W.E., et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 118 (2000), 264–273.
125. Regueiro, M., Schraut, W., Baidoo, L., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136 (2009), 441–450e1 quiz 716.
126. Mowat, C., Arnott, I., Cahill, A., et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 1 (2016), 273–282.
127. Rutgeerts, P., Geboes, K., Vantrappen, G., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 (1990), 956–963.
128. Guyatt, G., Mitchell, A., Irvine, E.J., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96 (1989), 804–810.
129. Peyrin-Biroulet, L., Reinisch, W., Colombel, J.F., et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 63 (2014), 88–95.
130. Kim, A.H., Roberts, C., Feagan, B.G., et al. Developing a standard set of patient-centred outcomes for inflammatory bowel disease: an international, cross-disciplinary consensus. J Crohns Colitis 12 (2018), 408–418.
131. Chen, X.L., Zhong, L.H., Wen, Y., et al. Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties. Health Qual Life Outcomes, 15, 2017, 177.
132. de Jong, M.J., Huibregtse, R., Masclee, A.A.M., et al. Patient-reported outcome measures for use in clinical trials and clinical practice in inflammatory bowel diseases: a systematic review. Clin Gastroenterol Hepatol 16 (2018), 648–663.
133. Van Deen, W.K., van der Meulen-de Jong, A.E., Parekh, N.K., et al. Development and validation of an inflammatory bowel diseases monitoring index for use with mobile health technologies. Clin Gastroenterol Hepatol 14 (2016), 1742–1750.e7.
134. Peyrin-Biroulet, L., Van Assche, G., Armuzzi, A., et al. Implementing the concept of continuous clinical response into clinical practice for ulcerative colitis. Clin Gastroenterol Hepatol 15 (2017), 1154–1161e1.
135. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109e1.
136. Ma, C., Panaccione, R., Fedorak, R.N., et al. Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set. Clin Gastroenterol Hepatol 16 (2018), 637–647.
137. Khanna, R., Zou, G., D'Haens, G., et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 65 (2016), 1119–1125.
138. Khanna, R., Zou, G., Stitt, L., et al. Responsiveness of endoscopic indices of disease activity for Crohn's disease. Am J Gastroenterol 112 (2017), 1584–1592.
139. Vuitton, L., Marteau, P., Sandborn, W.J., et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 65 (2016), 1447–1455.
140. Panes, J., Bouzas, R., Chaparro, M., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 34 (2011), 125–145.
141. Panes, J., Garcia-Olmo, D., Van Assche, G., et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 388 (2016), 1281–1290.
142. Pariente, B., Mary, J.Y., Danese, S., et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology 148 (2015), 52–63e3.
143. Mosli, M.H., Zou, G., Garg, S.K., et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110 (2015), 802–819 quiz 20.
144. Colombel, J.F., Panaccione, R., Bossuyt, P., et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390 (2018), 2779–2789.
145. Faubion, W.A. Jr., Fletcher, J.G., O'Byrne, S., et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 108 (2013), 1891–1900.